All Articles

Harrow's $100M deal for the first FDA-approved nasal spray for dry eye disease challenges the dominance of eye drops and reshapes its ophthalmic portfolio.

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

The utility's strong Q2 results are fueled by massive energy demand from new data centers, prompting a $1B capital plan increase and promising regional growth.

With a strong cash runway to 2028 and key data expected, Aclaris is advancing a multi-asset portfolio against complex immuno-inflammatory diseases.

Bob's Discount Furniture's impressive Q2 earnings reveal a dual victory: a value proposition resonating with cautious consumers and a massive tariff refund.

Despite a reported loss, DNOW's record cash flow, aggressive buybacks, and operational wins signal a powerful turnaround. Is this the new blueprint for resilience?

Lithium Americas secures crucial financing for its Nevada mega-project, a move to navigate peak construction costs and reinforce its role in U.S. EV independence.

Solid growth and a key FDA approval showcase Kenvue's value as it barrels toward a transformative merger, creating a new consumer health powerhouse.

Veritas Capital's acquisition of Saber Power isn't just a deal; it's a high-stakes play on the infrastructure backbone of the AI and data center boom.

Playtika's Q2 results reveal a strategic pivot. Soaring revenue and DTC growth mask a drop in paying users, signaling a disciplined focus on profit over scale.

Heartland Dental CEO Pat Bauer's Titan Award celebrates his 'doctor-led' vision. But what does this mean for an industry increasingly shaped by private equity?

F&G's steady dividend pleases income investors, but recent earnings misses and a complex capital structure warrant a closer look at its long-term health.

Cresco Labs posts a 15% revenue jump, touting operational wins ahead of federal reform. But a surprise CFO departure introduces a new variable.

Opal Therapeutics' organoid platform, backed by a major NSF award, bypasses failed animal models to fast-track cures for endometriosis and fibroids.

Greenland Energy is scaling back its winter drilling plan. It's not a retreat, but a strategic signal of caution in a high-stakes Arctic balancing act.

Lamar's stellar Q2 results, beating forecasts on all key metrics, signal robust health in the outdoor ad market and highlight its digital strategy's success.

Paramount Resources posts a blowout quarter with record-setting Montney wells, raising production guidance while holding spending flat—a feat of capital efficiency.

Enerflex's Q2 results reveal a masterclass in strategy. With a record backlog and fortified balance sheet, the firm is shedding assets to fund its future.

Arhaus reported record profits, but a one-time tariff refund tells only half the story. We dig into the numbers to find the real drivers of future growth.

Evolent Health touts soaring revenues and a major oncology deal, yet falling profits and rising medical costs reveal a challenging road ahead. Can AI deliver the efficiency it needs?